Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
NicOx SA
NicOx SA
Activities:
Research & Development
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Tabletability, compactability and compressibility: What’s the difference?
To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
Indian government bans three medicines owing to health risks
Decision follows strong stand on suspending marketing of all drugs prohibited for sale in other countries, including the US, UK, EU and Australia
Berry Global invests to increase production capacity for healthcare products
Berry Global Group has invested in additional assets and manufacturing capabilities to increase its healthcare production capacity by up to 30% across three of its European sites
Effective ways to optimise heat exchangers
Heat exchangers are used within a wide range of process industries as a way to transfer heat between two fluid streams across a medium in an energy conservative way
Upcoming event
BIO International Convention Digital
3-6 June, 2024 | Convention | San Diego, US
See all
Related Content
Research & Development
Nicox appoints Gavin Spencer as CEO
Spencer’s initial focus will be on securing financing to complete the Phase III trial of NCX 470, Denali
Recruitment
Nicox appoints Dr Tomas Navratil Head of Development
Research & Development
Lauren P. Silvernail appointed to Nicox Board of Directors
Renewal of the terms of office of Birgit Stattin Norinder and Michele Garufi
Finance
Nicox to transfer commercial operations to new company led by GHO Capital
The deal values Nicox's operations at up to €26m
Regulatory
US FDA grants priority review for Nicox's AC-170 new drug application
FDA assigns Prescription Drug User Fee Act (PDUFA) goal date of 18 October 2016
Finance
Nicox to buy Aciex Therapeutics
Part of strategy to create an international ophthalmic company built around therapeutics and diagnostics
Pharmaceutical
NicOx appoints three commercial executives in the US
In preparation for the launch of ophthalmic product AdenoPlus
Subscribe now